Drug intelligence / Profile preview

Decolic

Development stage: Phase 4
Lead developer: Kaiser Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Decolic is an oral suspension/syrup formulation manufactured by Kaiser Pharmaceutical (Kaiser Drugs Pvt Ltd). It is a combination product containing dicyclomine hydrochloride and simethicone. Dicyclomine is a small molecule anticholinergic agent that acts as an antispasmodic by blocking acetylcholine at muscarinic receptors on smooth muscle, thereby reducing gastrointestinal motility and cramping. Simethicone is an anti-foaming agent that reduces surface tension of gas bubbles, facilitating their expulsion and relieving bloating. Decolic is primarily indicated for the treatment of functional gastrointestinal disorders, including infantile colic, abdominal cramps, and irritable bowel syndrome (IBS) in pediatric populations.

Brand names: Decolic
Other names: Decolic SyrupDecolic Suspension

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on Decolic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Decolic.